Age-related Macular Degeneration (AMD) Drugs Market by Product (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre), Molecule (Ranibizumab, Aflibercept, Faricimab), Approval Type (Biologic, Biosimilar), Type of AMD, End User - Global Forecast to 2029
The Age-Related Macular Degeneration (AMD) Drugs market is projected to reach USD 17.37 Billion from 2029 USD 10.46 Billion in 2024 growing at a CAGR of 10.7% during the forecast period of 2024-2029.
Major pharmaceutical companies have reported a 2 fold increase in the geriatric population (above 60 years of age) by 2050, and this increase will have an impact on the number of AMD cases as AMD is associated with old age. Lifestyle factors such as smoking, diet, and physical activity also significantly influence AMD risk. For instance, studies have shown that smoking can accelerate the onset of AMD by an average of 5.5 years. According to the Macular Society (UK), smokers are likely to develop AMD up to 10 years earlier than non-smokers. Leading ophthalmologists from the UAE and UK have reported a decrease in the onset age of AMD and concluded that unhealthy lifestyle habits can bring down this age further by the next decade. Researchers from Japan conducted research to examine the effects of alcohol on AMD and concluded that moderate to heavy alcohol consumption increases the risk of early AMD. Similarly, a higher body mass index (BMI) is associated with an increased risk of both early and late AMD, as obesity and lack of physical activity are linked to increased oxidative stress and inflammation, contributing to AMD development. Rising incidences of AMD are driving companies to expand their drug pipeline and seek fast-track designations to advance their products' availability. For instance, in 2021 Opthea Limited received fast-track designation for its pipeline drug OPT-302 developed for the treatment of patients with wet AMD, advancing its development process. Similarly in 2023, Adverum Biotechnology received an Innovation Passport from the UK’s MHRA for its pipeline drug Ixo-vec (ixoberogene soroparvovec), helping to speed up patient access and regulatory support in the UK. These developments along with a rising number of AMD cases are projected to increase the demand for AMD drugs in the market.
“Vabysmo drug is set to register the highest growth during 2024-2029 in the Age-Related Macular degeneration (AMD) drugs market”
Based on products the Age-Related Macular Degeneration (AMD) drugs market is segmented into Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre, and other products including Beovu, Conbercept, Byooviz, and Izervay among others. Vabysmo (faricimab-svoa) is set to register the highest growth rate during the forecast period of 2024-2029, owing to the positive feedback received from patients and ophthalmologists for the treatment of AMD. The rising adoption of the drug is also supported by the 4x increase in the revenue of the drug from 2022 to 2023. Studies conducted to test the efficacy and tolerability of the drug have concluded that the drug is well tolerated in people with retinal disorders and can preserve vision while reducing the frequency of injections elevating the treatment burden of the patients. The drug is also used for the treatment of patients who showed resistance to the treatment from Eylea (aflibercept) and has significant improvement in visual acuity.
“Hospitals to witness the high growth in the AMD drugs market by End User”
Based on end users, the age-related macular degeneration (AMD) drugs market is segmented into hospitals, specialty centers, and long-term care facilities. Hospitals are projected to witness the highest growth rate during the forecast period of 2024-2029. This growth can be attributed to factors such as the ability of hospitals to provide comprehensive care to patients through advanced healthcare infrastructure and specialized treatment facilities. Additionally, hospitals are more abundant than any other end user (Specialty centers and Long-term care facilities) and modern hospitals are generally multispeciality in nature offering specialized treatment. Hospitals often collaborate with long-term care (LTC) facilities to provide support such as ophthalmologists for the treatment of individuals living in the care facility. Moreover, hospitals also partner with pharmaceutical companies to ensure an optimal supply of AMD drugs for the patients.
“Biologics segment accounted for the highest growth rate in the Age-Related Macular Degeneration (AMD) drugs market by approval type”
Based on approval type, the age-related macular degeneration (AMD) drugs market is segmented into biologics and biosimilars. During the forecast period of 2024-2029, biologics are projected to register the highest growth in the AMD drugs market by approval type. This high growth can be attributed to the increase in the number of approvals for biologics such as Vabysmo, Eylea HD, Syfovre, and Izervay, among others, for the treatment of AMD. Moreover, as these drugs are recently approved they are protected by patents and generally prevent biosimilar entry into the market. Additionally, improved reimbursement policies and comprehensive insurance coverage offered for biologics generally deter patients and ophthalmologists from choosing biosimilars over biologics. New innovative companies are also developing novel biologics for treating various forms of AMD supporting the growth of this segment.
“North America: The fastest-growing country in the Age-Related Macular Degeneration (AMD) drugs market”
The Age-Related Macular Degeneration (AMD) drugs market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is projected to register the highest CAGR during the forecast period. Factors such as rising AMD cases due to an increase in the geriatric population and accompanied by unhealthy lifestyle and dietary habits, and increasing pharmaceutical R&D spending, by major pharmaceutical and biotechnology companies present in the region, to develop novel therapies and drug delivery systems for AMD disease are driving the growth of AMD drugs in the region. Additionally, growing public-private partnerships, increasing government support and improved reimbursement policies further support the growth of the AMD drugs market in this region.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the age-related macular degeneration (AMD) drugs market. It aims at estimating the size and future growth potential of the market across different segments, such as products, molecules, type of AMD, approval type, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Reasons to Buy the Report:
The report provides insights on the following pointers:
Major pharmaceutical companies have reported a 2 fold increase in the geriatric population (above 60 years of age) by 2050, and this increase will have an impact on the number of AMD cases as AMD is associated with old age. Lifestyle factors such as smoking, diet, and physical activity also significantly influence AMD risk. For instance, studies have shown that smoking can accelerate the onset of AMD by an average of 5.5 years. According to the Macular Society (UK), smokers are likely to develop AMD up to 10 years earlier than non-smokers. Leading ophthalmologists from the UAE and UK have reported a decrease in the onset age of AMD and concluded that unhealthy lifestyle habits can bring down this age further by the next decade. Researchers from Japan conducted research to examine the effects of alcohol on AMD and concluded that moderate to heavy alcohol consumption increases the risk of early AMD. Similarly, a higher body mass index (BMI) is associated with an increased risk of both early and late AMD, as obesity and lack of physical activity are linked to increased oxidative stress and inflammation, contributing to AMD development. Rising incidences of AMD are driving companies to expand their drug pipeline and seek fast-track designations to advance their products' availability. For instance, in 2021 Opthea Limited received fast-track designation for its pipeline drug OPT-302 developed for the treatment of patients with wet AMD, advancing its development process. Similarly in 2023, Adverum Biotechnology received an Innovation Passport from the UK’s MHRA for its pipeline drug Ixo-vec (ixoberogene soroparvovec), helping to speed up patient access and regulatory support in the UK. These developments along with a rising number of AMD cases are projected to increase the demand for AMD drugs in the market.
“Vabysmo drug is set to register the highest growth during 2024-2029 in the Age-Related Macular degeneration (AMD) drugs market”
Based on products the Age-Related Macular Degeneration (AMD) drugs market is segmented into Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre, and other products including Beovu, Conbercept, Byooviz, and Izervay among others. Vabysmo (faricimab-svoa) is set to register the highest growth rate during the forecast period of 2024-2029, owing to the positive feedback received from patients and ophthalmologists for the treatment of AMD. The rising adoption of the drug is also supported by the 4x increase in the revenue of the drug from 2022 to 2023. Studies conducted to test the efficacy and tolerability of the drug have concluded that the drug is well tolerated in people with retinal disorders and can preserve vision while reducing the frequency of injections elevating the treatment burden of the patients. The drug is also used for the treatment of patients who showed resistance to the treatment from Eylea (aflibercept) and has significant improvement in visual acuity.
“Hospitals to witness the high growth in the AMD drugs market by End User”
Based on end users, the age-related macular degeneration (AMD) drugs market is segmented into hospitals, specialty centers, and long-term care facilities. Hospitals are projected to witness the highest growth rate during the forecast period of 2024-2029. This growth can be attributed to factors such as the ability of hospitals to provide comprehensive care to patients through advanced healthcare infrastructure and specialized treatment facilities. Additionally, hospitals are more abundant than any other end user (Specialty centers and Long-term care facilities) and modern hospitals are generally multispeciality in nature offering specialized treatment. Hospitals often collaborate with long-term care (LTC) facilities to provide support such as ophthalmologists for the treatment of individuals living in the care facility. Moreover, hospitals also partner with pharmaceutical companies to ensure an optimal supply of AMD drugs for the patients.
“Biologics segment accounted for the highest growth rate in the Age-Related Macular Degeneration (AMD) drugs market by approval type”
Based on approval type, the age-related macular degeneration (AMD) drugs market is segmented into biologics and biosimilars. During the forecast period of 2024-2029, biologics are projected to register the highest growth in the AMD drugs market by approval type. This high growth can be attributed to the increase in the number of approvals for biologics such as Vabysmo, Eylea HD, Syfovre, and Izervay, among others, for the treatment of AMD. Moreover, as these drugs are recently approved they are protected by patents and generally prevent biosimilar entry into the market. Additionally, improved reimbursement policies and comprehensive insurance coverage offered for biologics generally deter patients and ophthalmologists from choosing biosimilars over biologics. New innovative companies are also developing novel biologics for treating various forms of AMD supporting the growth of this segment.
“North America: The fastest-growing country in the Age-Related Macular Degeneration (AMD) drugs market”
The Age-Related Macular Degeneration (AMD) drugs market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is projected to register the highest CAGR during the forecast period. Factors such as rising AMD cases due to an increase in the geriatric population and accompanied by unhealthy lifestyle and dietary habits, and increasing pharmaceutical R&D spending, by major pharmaceutical and biotechnology companies present in the region, to develop novel therapies and drug delivery systems for AMD disease are driving the growth of AMD drugs in the region. Additionally, growing public-private partnerships, increasing government support and improved reimbursement policies further support the growth of the AMD drugs market in this region.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side -70% and Demand Side – 30%
- By Designation: Managers -45%, CXOs and Directors -30%, and Executives – 25%
- By Region: North America-35%, Europe -25%, Asia-Pacific -15%, Latin America-10%, Middle East-10% and Africa-5%
- Regeneron Pharmaceuticals Inc. (US)
- Bayer AG (Germany)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Novartis AG (Switzerland)
- Apellis Pharmaceuticals (US)
- Coherus BioSciences (US)
- Astellas Pharma Inc. (Japan)
- Biogen (US)
- STADA Arzneimittel AG (Germany)
- Formycon AG (Germany)
- Biocon. (India)
- Outlook Therapeutics, Inc. (US)
- Intas Pharmaceuticals Ltd. (India)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Chengdu Kanghong Biotech Company (China)
- Sandoz Group AG (Switzerland)
- Stealth BioTherapeutics Inc. (US)
- Ocular Therapeutix, Inc. (US)
- Opthea Limited (Australia)
- Kodiak Sciences Inc. (US)
- Innovent Biologics, Inc. (China)
- Bio-Thera Solution (China)
- Alvotech (Iceland)
- Alteogen Inc. (South Korea)
- Shanghai Henlius Biotech, Inc. (China)
- Amgen Inc. (US)
- Ocumension Therapeutics. (China)
- Adverum Biotechnologies, Inc. (US)
This report provides a detailed picture of the age-related macular degeneration (AMD) drugs market. It aims at estimating the size and future growth potential of the market across different segments, such as products, molecules, type of AMD, approval type, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Reasons to Buy the Report:
The report provides insights on the following pointers:
- Analysis of key drivers (Increasing risk of AMD due to changing lifestyle and dietary habits, Steady development and approvals of drugs and Favorable reimbursement and insurance policies), restraints (Off-Label Use of Drugs), opportunities (Shifting Focus on New Drug Modalities, Rapidly expanding market in developing countries, Need to address dry age-macular degeneration and geographic atrophy), and challenges (Non-adherence to treatments) influencing the growth of the Age-Related Macular Degeneration (AMD) durgs market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new therapy launches in the Age-Related Macular Degeneration (AMD) drugs market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various opportunities and developments across key geographic regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Age-Related Macular Degeneration (AMD) drugs market.
- Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players like Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), and Novartis AG (Switzerland) among others in the Age-Related Macular Degeneration (AMD) drugs market.
INTRODUCTION
1. STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS AND EXCLUSIONS
1.4 STUDY SCOPE
1.4. MARKETS COVERED
1.4.2 YEARS CONSIDERED
1.4.3 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 IMPACT OF AI ON AGE-RELATED MACULAR DEGENERATION DRUGS MARKET
2 RESEARCH METHODOLOGY
2. RESEARCH DATA
2.1. SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2. BOTTOM-UP APPROACH
2.3 MARKET GROWTH FORECAST
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4. AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET OVERVIEW
4.2 NORTH AMERICAN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SHARE, BY APPROVAL TYPE AND COUNTRY, 2023
4.3 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF
AMD, 2024 VS. 2029 (USD MILLION)
4.4 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2023
4.5 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:
GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5. INTRODUCTION
5.2 MARKET DYNAMICS
5.2. DRIVERS
5.2.1. Changing lifestyle and dietary habits
5.2.1.2 Steady development and approvals of drugs
5.2.1.3 Favorable reimbursement and insurance policies
5.2.2 RESTRAINTS
5.2.2. Off-label use of drugs
5.2.3 OPPORTUNITIES
5.2.3. Shifting focus on new drug modalities
5.2.3.2 Rapidly expanding market in developing countries
5.2.3.3 Need to address dry age-related macular degeneration and geographic atrophy
5.2.4 CHALLENGES
5.2.4. Non-adherence to treatments
5.3 TECHNOLOGY ANALYSIS
5.3. KEY TECHNOLOGIES
5.3.1. Hybridoma technology
5.3.1.2 Recombinant DNA technology
5.3.1.3 Antibody engineering
5.3.2 ADJACENT TECHNOLOGIES
5.3.2. Tissue engineering (scaffold technology)
5.3.2.2 Artificial intelligence
5.3.2.3 Optogenetic technology
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.5 PRICING ANALYSIS
5.5. AVERAGE SELLING PRICING OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY PRODUCT (PER DOSE)
5.5.2 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY REGION
5.5.3 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY KEY PLAYER
5.6 VALUE CHAIN ANALYSIS
5.7 SUPPLY CHAIN ANALYSIS
5.8 ECOSYSTEM ANALYSIS
5.9 PATENT ANALYSIS
5.10 REGULATORY ANALYSIS
5.10. REGULATORY LANDSCAPE
5.10.1. US
5.10.1.2 Europe
5.10.1.3 Emerging economies
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.11. INTENSITY OF COMPETITIVE RIVALRY
5.11.2 BARGAINING POWER OF SUPPLIERS
5.11.3 BARGAINING POWER OF BUYERS
5.11.4 THREAT OF SUBSTITUTES
5.11.5 THREAT OF NEW ENTRANTS
5.12 KEY CONFERENCES AND EVENTS, 2024–2025
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13. KEY STAKEHOLDERS IN BUYING PROCESS
5.13.2 BUYING CRITERIA
5.14 INVESTMENT/FUNDING ACTIVITY
5.15 PIPELINE ANALYSIS
5.16 CASE STUDY ANALYSIS
5.16. IMPROVED EFFICACY OF RGX-314 FOR WET AGE-RELATED
MACULAR DEGENERATION TREATMENT
5.16.2 ENHANCED EFFICACY OF EYLEA HD FOR WET AGE-RELATED
MACULAR DEGENERATION TREATMENT
5.16.3 HIGHER EFFICACY AND SAFETY OF FARICIMAB FOR NEOVASCULAR
AGE-RELATED MACULAR DEGENERATION TREATMENT
5.17 IMPACT OF AI ON AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET
6 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,
BY PRODUCT
6. INTRODUCTION
6.2 EYLEA & EYLEA HD
6.2. HIGHER PREFERENCE BY OPHTHALMOLOGISTS AND PATIENTS
TO SPEED UP GROWTH
6.3 LUCENTIS
6.3. PROVEN ABILITY TO IMPROVE VISUAL ACUITY AND RETINAL
THICKNESS TO FAVOR GROWTH
6.4 VABYSMO
6.4. FAVORABLE APPROVAL FROM GOVERNMENT AUTHORITIES
TO SUSTAIN GROWTH
6.5 SYFOVRE
6.5. INCREASING PREVALENCE OF ADVANCED DRY AGE-RELATED
MACULAR DEGENERATION TO BOOST MARKET
6.6 OTHER PRODUCTS
7 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,
BY MOLECULE
7. INTRODUCTION
7.2 AFLIBERCEPT
7.2. HIGHER EFFICIENCY IN TREATING RETINAL DISORDERS
TO EXPEDITE GROWTH
7.3 FARICIMAB
7.3. FAVORABLE ADOPTION AND OUTCOMES OF RESEARCH
STUDIES TO AUGMENT GROWTH
7.4 RANIBIZUMAB
7.4. ENHANCED RESULTS COMPARED TO LASER TREATMENT TO DRIVE MARKET
7.5 PEGCETACOPLAN
7.5. HIGHER ADOPTION IN TREATING GEOGRAPHIC ATROPHY TO
CONTRIBUTE TO GROWTH
7.6 OTHER MOLECULES
8 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,
BY APPROVAL TYPE
8. INTRODUCTION
8.2 BIOLOGICS
8.2. HIGHER CLINICAL VALIDATION AND REGULATORY ADVANTAGES
TO SUPPORT GROWTH
8.3 BIOSIMILARS
8.3. LOW DEVELOPMENT AND APPROVAL TO FAVOR MARKET GROWTH
9 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,
BY TYPE OF AMD
9. INTRODUCTION
9.2 WET AMD
9.2. GROWING GERIATRIC POPULATION TO FACILITATE GROWTH
9.3 DRY AMD
9.3. INCREASED RESEARCH & DEVELOPMENT EFFORTS TO PROMOTE GROWTH
10 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,
BY END USER
10. INTRODUCTION
10.2 HOSPITALS
10.2. GROWING COLLABORATIONS BETWEEN HOSPITALS AND PHARMACEUTICAL COMPANIES TO STIMULATE GROWTH
10.3 LONG-TERM CARE FACILITIES
10.3. NEED FOR SUSTAINED MEDICAL SUPERVISION AND SUPPORT FOR CHRONIC CONDITIONS TO FUEL MARKET
10.4 SPECIALTY CENTERS
10.4. RISING INCLINATION TOWARD PERSONALIZED TREATMENT PLANS TO ACCELERATE GROWTH
1 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION
11. INTRODUCTION
11.2 NORTH AMERICA
11.2. MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2. Rising investment in healthcare research & development
to propel market
11.2.3 CANADA
11.2.3. Favorable government initiatives to aid market growth
11.3 EUROPE
11.3. MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2. Rising focus on clinical research with public-private partnerships to augment growth
11.3.3 UK
11.3.3. Ongoing technological advancements to promote growth
11.3.4 FRANCE
11.3.4. Growing investments in funding healthcare and allied technology to foster growth
11.3.5 ITALY
11.3.5. Comprehensive treatment coverage and funding for new therapies to fuel market
11.3.6 SPAIN
11.3.6. Growing number of collaborative projects to favor market growth
11.3.7 NETHERLANDS
11.3.7. Increasing focus of clinical trials on biomarkers and hereditary conditions to drive market
11.3.8 REST OF EUROPE
11.4 ASIA PACIFIC
11.4. MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 CHINA
11.4.2. Strategic drug approvals to support market growth
11.4.3 JAPAN
11.4.3. Advanced healthcare infrastructure to encourage growth
11.4.4 INDIA
11.4.4. Regulatory reforms and aging population to boost market
11.4.5 AUSTRALIA
11.4.5. Increasing disease incidence and evolving treatment options to facilitate growth
11.4.6 SOUTH KOREA
11.4.6. Supportive regulatory environment to boost market
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5. MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.2. Increasing rate of visual impairment to sustain growth
11.5.3 MEXICO
11.5.3. Growing research initiatives for alternative medicines and nano-based drug delivery system to speed up growth
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST
11.6. MACROECONOMIC OUTLOOK FOR MIDDLE EAST
11.6.2 GCC COUNTRIES
11.6.2. Saudi Arabia
11.6.2.1. Sustained health coverage and biosimilar drug approvals to propel market
11.6.2.2 UAE
11.6.2.2. Increasing focus on technological advancements, ongoing research, and government initiatives to support growth
11.6.2.3 Other GCC Countries
11.6.3 REST OF MIDDLE EAST
11.7 AFRICA
11.7. GROWING PREVALENCE OF PATIENT ADVOCACY GROUPS AND REGULATORY IMPROVEMENTS TO DRIVE MARKET
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
12 COMPETITIVE LANDSCAPE
12. OVERVIEW
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
12.2. OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET
12.3 REVENUE ANALYSIS, 2021–2023
12.4 MARKET SHARE ANALYSIS, 2023
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.5. STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.5.5. Company footprint
12.5.5.2 Molecule footprint
12.5.5.3 Approval footprint
12.5.5.4 Type of AMD footprint
12.5.5.5 Region footprint
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.6. PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
12.7 COMPANY VALUATION AND FINANCIAL METRICS
12.7. COMPANY VALUATION
12.7.2 FINANCIAL METRICS
12.8 BRAND/PRODUCT COMPARISON
12.9 COMPETITIVE SCENARIO
12.9. PRODUCT LAUNCHES & APPROVALS
12.9.2 DEALS
12.9.3 EXPANSIONS
13 COMPANY PROFILES
13. KEY PLAYERS
13.1. F. HOFFMANN-LA ROCHE LTD
13.1.1. Business overview
13.1.1.2 Products offered
13.1.1.3 Recent developments
13.1.1.3. Product launches & approvals
13.1.1.4 MnM view
13.1.1.4. Right to win
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses and competitive threats
13.1.2 REGENERON PHARMACEUTICALS INC.
13.1.2. Business overview
13.1.2.2 Products offered
13.1.2.3 Recent developments
13.1.2.3. Product launches & approvals
13.1.2.4 MnM view
13.1.2.4. Right to win
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses and competitive threats
13.1.3 NOVARTIS AG
13.1.3. Business overview
13.1.3.2 Products offered
13.1.3.3 Recent developments
13.1.3.3. Product launches & approvals
13.1.3.3.2 Deals
13.1.3.4 MnM view
13.1.3.4. Right to win
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses and competitive threats
13.1.4 BAYER AG
13.1.4. Business overview
13.1.4.2 Products offered
13.1.4.3 Recent developments
13.1.4.3. Product launches & approvals
13.1.4.4 MnM view
13.1.4.4. Right to win
13.1.4.4.2 Strategic choices
13.1.4.4.3 Weaknesses and competitive threats
13.1.5 APELLIS PHARMACEUTICALS
13.1.5. Business overview
13.1.5.2 Products offered
13.1.5.3 Recent developments
13.1.5.3. Product launches & approvals
13.1.5.3.2 Deals
13.1.5.4 MnM view
13.1.5.4. Right to win
13.1.5.4.2 Strategic choices
13.1.5.4.2. Weaknesses and competitive threats
13.1.6 ASTELLAS PHARMA INC.
13.1.6. Business overview
13.1.6.2 Products offered
13.1.6.3 Recent developments
13.1.6.3. Product launches & approvals
13.1.6.3.2 Deals
13.1.7 STADA ARZNEIMITTEL AG
13.1.7. Business overview
13.1.7.2 Products offered
13.1.7.3 Recent developments
13.1.7.3. Product launches & approvals
13.1.7.3.2 Deals
13.1.8 BIOGEN
13.1.8. Business overview
13.1.8.2 Products offered
13.1.8.3 Recent developments
13.1.8.3. Product launches & approvals
13.1.9 FORMYCON AG
13.1.9. Business overview
13.1.9.2 Products offered
13.1.9.3 Recent developments
13.1.9.3. Product launches & approvals
13.1.9.3.2 Deals
13.1.10 COHERUS BIOSCIENCES
13.1.10. Business overview
13.1.10.2 Products offered
13.1.10.3 Recent developments
13.1.10.3. Products launches & approvals
13.1.10.3.2 Other developments
13.1.1 BIOCON
13.1.11. Business overview
13.1.11.2 Product offered
13.1.11.3 Recent developments
13.1.11.3. Product launches & approvals
13.1.11.3.2 Deals
13.1.12 OUTLOOK THERAPEUTICS, INC.
13.1.12. Business overview
13.1.12.2 Products offered
13.1.12.3 Recent developments
13.1.12.3. Product launches & approvals
13.1.12.3.2 Deals
13.1.13 TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.1.13. Business overview
13.1.13.2 Products offered
13.1.13.3 Recent developments
13.1.13.3. Product launches & approvals
13.1.13.3.2 Deals
13.1.14 INTAS PHARMACEUTICALS LTD.
13.1.14. Business overview
13.1.14.2 Products offered
13.1.15 SANDOZ GROUP AG
13.1.15. Business overview
13.1.15.2 Products offered
13.1.15.3 Recent developments
13.1.15.3. Product launches & approvals
13.1.15.3.2 Deals
13.1.15.3.3 Expansions
13.1.16 CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD.
13.1.16. Business overview
13.1.16.2 Products offered
13.2 OTHER PLAYERS
13.2. OCULAR THERAPEUTIX, INC.
13.2.2 OPTHEA LIMITED
13.2.3 KODIAK SCIENCES INC.
13.2.4 BIO-THERA
13.2.5 AMGEN INC.
13.2.6 ALVOTECH
13.2.7 STEALTH BIOTHERAPEUTICS INC.
13.2.8 ALTEOGEN INC.
13.2.9 OCUMENSION THERAPEUTICS
13.2.10 INNOVENT
13.2.1 SHANGHAI HENLIUS BIOTECH, INC.
14 APPENDIX
14. DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
1. STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS AND EXCLUSIONS
1.4 STUDY SCOPE
1.4. MARKETS COVERED
1.4.2 YEARS CONSIDERED
1.4.3 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 IMPACT OF AI ON AGE-RELATED MACULAR DEGENERATION DRUGS MARKET
2 RESEARCH METHODOLOGY
2. RESEARCH DATA
2.1. SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2. BOTTOM-UP APPROACH
2.3 MARKET GROWTH FORECAST
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4. AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET OVERVIEW
4.2 NORTH AMERICAN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SHARE, BY APPROVAL TYPE AND COUNTRY, 2023
4.3 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF
AMD, 2024 VS. 2029 (USD MILLION)
4.4 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2023
4.5 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:
GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5. INTRODUCTION
5.2 MARKET DYNAMICS
5.2. DRIVERS
5.2.1. Changing lifestyle and dietary habits
5.2.1.2 Steady development and approvals of drugs
5.2.1.3 Favorable reimbursement and insurance policies
5.2.2 RESTRAINTS
5.2.2. Off-label use of drugs
5.2.3 OPPORTUNITIES
5.2.3. Shifting focus on new drug modalities
5.2.3.2 Rapidly expanding market in developing countries
5.2.3.3 Need to address dry age-related macular degeneration and geographic atrophy
5.2.4 CHALLENGES
5.2.4. Non-adherence to treatments
5.3 TECHNOLOGY ANALYSIS
5.3. KEY TECHNOLOGIES
5.3.1. Hybridoma technology
5.3.1.2 Recombinant DNA technology
5.3.1.3 Antibody engineering
5.3.2 ADJACENT TECHNOLOGIES
5.3.2. Tissue engineering (scaffold technology)
5.3.2.2 Artificial intelligence
5.3.2.3 Optogenetic technology
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.5 PRICING ANALYSIS
5.5. AVERAGE SELLING PRICING OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY PRODUCT (PER DOSE)
5.5.2 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY REGION
5.5.3 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY KEY PLAYER
5.6 VALUE CHAIN ANALYSIS
5.7 SUPPLY CHAIN ANALYSIS
5.8 ECOSYSTEM ANALYSIS
5.9 PATENT ANALYSIS
5.10 REGULATORY ANALYSIS
5.10. REGULATORY LANDSCAPE
5.10.1. US
5.10.1.2 Europe
5.10.1.3 Emerging economies
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.11. INTENSITY OF COMPETITIVE RIVALRY
5.11.2 BARGAINING POWER OF SUPPLIERS
5.11.3 BARGAINING POWER OF BUYERS
5.11.4 THREAT OF SUBSTITUTES
5.11.5 THREAT OF NEW ENTRANTS
5.12 KEY CONFERENCES AND EVENTS, 2024–2025
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13. KEY STAKEHOLDERS IN BUYING PROCESS
5.13.2 BUYING CRITERIA
5.14 INVESTMENT/FUNDING ACTIVITY
5.15 PIPELINE ANALYSIS
5.16 CASE STUDY ANALYSIS
5.16. IMPROVED EFFICACY OF RGX-314 FOR WET AGE-RELATED
MACULAR DEGENERATION TREATMENT
5.16.2 ENHANCED EFFICACY OF EYLEA HD FOR WET AGE-RELATED
MACULAR DEGENERATION TREATMENT
5.16.3 HIGHER EFFICACY AND SAFETY OF FARICIMAB FOR NEOVASCULAR
AGE-RELATED MACULAR DEGENERATION TREATMENT
5.17 IMPACT OF AI ON AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET
6 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,
BY PRODUCT
6. INTRODUCTION
6.2 EYLEA & EYLEA HD
6.2. HIGHER PREFERENCE BY OPHTHALMOLOGISTS AND PATIENTS
TO SPEED UP GROWTH
6.3 LUCENTIS
6.3. PROVEN ABILITY TO IMPROVE VISUAL ACUITY AND RETINAL
THICKNESS TO FAVOR GROWTH
6.4 VABYSMO
6.4. FAVORABLE APPROVAL FROM GOVERNMENT AUTHORITIES
TO SUSTAIN GROWTH
6.5 SYFOVRE
6.5. INCREASING PREVALENCE OF ADVANCED DRY AGE-RELATED
MACULAR DEGENERATION TO BOOST MARKET
6.6 OTHER PRODUCTS
7 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,
BY MOLECULE
7. INTRODUCTION
7.2 AFLIBERCEPT
7.2. HIGHER EFFICIENCY IN TREATING RETINAL DISORDERS
TO EXPEDITE GROWTH
7.3 FARICIMAB
7.3. FAVORABLE ADOPTION AND OUTCOMES OF RESEARCH
STUDIES TO AUGMENT GROWTH
7.4 RANIBIZUMAB
7.4. ENHANCED RESULTS COMPARED TO LASER TREATMENT TO DRIVE MARKET
7.5 PEGCETACOPLAN
7.5. HIGHER ADOPTION IN TREATING GEOGRAPHIC ATROPHY TO
CONTRIBUTE TO GROWTH
7.6 OTHER MOLECULES
8 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,
BY APPROVAL TYPE
8. INTRODUCTION
8.2 BIOLOGICS
8.2. HIGHER CLINICAL VALIDATION AND REGULATORY ADVANTAGES
TO SUPPORT GROWTH
8.3 BIOSIMILARS
8.3. LOW DEVELOPMENT AND APPROVAL TO FAVOR MARKET GROWTH
9 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,
BY TYPE OF AMD
9. INTRODUCTION
9.2 WET AMD
9.2. GROWING GERIATRIC POPULATION TO FACILITATE GROWTH
9.3 DRY AMD
9.3. INCREASED RESEARCH & DEVELOPMENT EFFORTS TO PROMOTE GROWTH
10 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,
BY END USER
10. INTRODUCTION
10.2 HOSPITALS
10.2. GROWING COLLABORATIONS BETWEEN HOSPITALS AND PHARMACEUTICAL COMPANIES TO STIMULATE GROWTH
10.3 LONG-TERM CARE FACILITIES
10.3. NEED FOR SUSTAINED MEDICAL SUPERVISION AND SUPPORT FOR CHRONIC CONDITIONS TO FUEL MARKET
10.4 SPECIALTY CENTERS
10.4. RISING INCLINATION TOWARD PERSONALIZED TREATMENT PLANS TO ACCELERATE GROWTH
1 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION
11. INTRODUCTION
11.2 NORTH AMERICA
11.2. MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2. Rising investment in healthcare research & development
to propel market
11.2.3 CANADA
11.2.3. Favorable government initiatives to aid market growth
11.3 EUROPE
11.3. MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2. Rising focus on clinical research with public-private partnerships to augment growth
11.3.3 UK
11.3.3. Ongoing technological advancements to promote growth
11.3.4 FRANCE
11.3.4. Growing investments in funding healthcare and allied technology to foster growth
11.3.5 ITALY
11.3.5. Comprehensive treatment coverage and funding for new therapies to fuel market
11.3.6 SPAIN
11.3.6. Growing number of collaborative projects to favor market growth
11.3.7 NETHERLANDS
11.3.7. Increasing focus of clinical trials on biomarkers and hereditary conditions to drive market
11.3.8 REST OF EUROPE
11.4 ASIA PACIFIC
11.4. MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 CHINA
11.4.2. Strategic drug approvals to support market growth
11.4.3 JAPAN
11.4.3. Advanced healthcare infrastructure to encourage growth
11.4.4 INDIA
11.4.4. Regulatory reforms and aging population to boost market
11.4.5 AUSTRALIA
11.4.5. Increasing disease incidence and evolving treatment options to facilitate growth
11.4.6 SOUTH KOREA
11.4.6. Supportive regulatory environment to boost market
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5. MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.2. Increasing rate of visual impairment to sustain growth
11.5.3 MEXICO
11.5.3. Growing research initiatives for alternative medicines and nano-based drug delivery system to speed up growth
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST
11.6. MACROECONOMIC OUTLOOK FOR MIDDLE EAST
11.6.2 GCC COUNTRIES
11.6.2. Saudi Arabia
11.6.2.1. Sustained health coverage and biosimilar drug approvals to propel market
11.6.2.2 UAE
11.6.2.2. Increasing focus on technological advancements, ongoing research, and government initiatives to support growth
11.6.2.3 Other GCC Countries
11.6.3 REST OF MIDDLE EAST
11.7 AFRICA
11.7. GROWING PREVALENCE OF PATIENT ADVOCACY GROUPS AND REGULATORY IMPROVEMENTS TO DRIVE MARKET
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
12 COMPETITIVE LANDSCAPE
12. OVERVIEW
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
12.2. OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET
12.3 REVENUE ANALYSIS, 2021–2023
12.4 MARKET SHARE ANALYSIS, 2023
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.5. STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.5.5. Company footprint
12.5.5.2 Molecule footprint
12.5.5.3 Approval footprint
12.5.5.4 Type of AMD footprint
12.5.5.5 Region footprint
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.6. PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
12.7 COMPANY VALUATION AND FINANCIAL METRICS
12.7. COMPANY VALUATION
12.7.2 FINANCIAL METRICS
12.8 BRAND/PRODUCT COMPARISON
12.9 COMPETITIVE SCENARIO
12.9. PRODUCT LAUNCHES & APPROVALS
12.9.2 DEALS
12.9.3 EXPANSIONS
13 COMPANY PROFILES
13. KEY PLAYERS
13.1. F. HOFFMANN-LA ROCHE LTD
13.1.1. Business overview
13.1.1.2 Products offered
13.1.1.3 Recent developments
13.1.1.3. Product launches & approvals
13.1.1.4 MnM view
13.1.1.4. Right to win
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses and competitive threats
13.1.2 REGENERON PHARMACEUTICALS INC.
13.1.2. Business overview
13.1.2.2 Products offered
13.1.2.3 Recent developments
13.1.2.3. Product launches & approvals
13.1.2.4 MnM view
13.1.2.4. Right to win
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses and competitive threats
13.1.3 NOVARTIS AG
13.1.3. Business overview
13.1.3.2 Products offered
13.1.3.3 Recent developments
13.1.3.3. Product launches & approvals
13.1.3.3.2 Deals
13.1.3.4 MnM view
13.1.3.4. Right to win
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses and competitive threats
13.1.4 BAYER AG
13.1.4. Business overview
13.1.4.2 Products offered
13.1.4.3 Recent developments
13.1.4.3. Product launches & approvals
13.1.4.4 MnM view
13.1.4.4. Right to win
13.1.4.4.2 Strategic choices
13.1.4.4.3 Weaknesses and competitive threats
13.1.5 APELLIS PHARMACEUTICALS
13.1.5. Business overview
13.1.5.2 Products offered
13.1.5.3 Recent developments
13.1.5.3. Product launches & approvals
13.1.5.3.2 Deals
13.1.5.4 MnM view
13.1.5.4. Right to win
13.1.5.4.2 Strategic choices
13.1.5.4.2. Weaknesses and competitive threats
13.1.6 ASTELLAS PHARMA INC.
13.1.6. Business overview
13.1.6.2 Products offered
13.1.6.3 Recent developments
13.1.6.3. Product launches & approvals
13.1.6.3.2 Deals
13.1.7 STADA ARZNEIMITTEL AG
13.1.7. Business overview
13.1.7.2 Products offered
13.1.7.3 Recent developments
13.1.7.3. Product launches & approvals
13.1.7.3.2 Deals
13.1.8 BIOGEN
13.1.8. Business overview
13.1.8.2 Products offered
13.1.8.3 Recent developments
13.1.8.3. Product launches & approvals
13.1.9 FORMYCON AG
13.1.9. Business overview
13.1.9.2 Products offered
13.1.9.3 Recent developments
13.1.9.3. Product launches & approvals
13.1.9.3.2 Deals
13.1.10 COHERUS BIOSCIENCES
13.1.10. Business overview
13.1.10.2 Products offered
13.1.10.3 Recent developments
13.1.10.3. Products launches & approvals
13.1.10.3.2 Other developments
13.1.1 BIOCON
13.1.11. Business overview
13.1.11.2 Product offered
13.1.11.3 Recent developments
13.1.11.3. Product launches & approvals
13.1.11.3.2 Deals
13.1.12 OUTLOOK THERAPEUTICS, INC.
13.1.12. Business overview
13.1.12.2 Products offered
13.1.12.3 Recent developments
13.1.12.3. Product launches & approvals
13.1.12.3.2 Deals
13.1.13 TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.1.13. Business overview
13.1.13.2 Products offered
13.1.13.3 Recent developments
13.1.13.3. Product launches & approvals
13.1.13.3.2 Deals
13.1.14 INTAS PHARMACEUTICALS LTD.
13.1.14. Business overview
13.1.14.2 Products offered
13.1.15 SANDOZ GROUP AG
13.1.15. Business overview
13.1.15.2 Products offered
13.1.15.3 Recent developments
13.1.15.3. Product launches & approvals
13.1.15.3.2 Deals
13.1.15.3.3 Expansions
13.1.16 CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD.
13.1.16. Business overview
13.1.16.2 Products offered
13.2 OTHER PLAYERS
13.2. OCULAR THERAPEUTIX, INC.
13.2.2 OPTHEA LIMITED
13.2.3 KODIAK SCIENCES INC.
13.2.4 BIO-THERA
13.2.5 AMGEN INC.
13.2.6 ALVOTECH
13.2.7 STEALTH BIOTHERAPEUTICS INC.
13.2.8 ALTEOGEN INC.
13.2.9 OCUMENSION THERAPEUTICS
13.2.10 INNOVENT
13.2.1 SHANGHAI HENLIUS BIOTECH, INC.
14 APPENDIX
14. DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
